Cardiovascular Diseases and Conditions Infographics

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is involved in cholesterol homeostasis and inflammation, platelet activation, and atherosclerosis disease progression.
This infographic presents the physiological functions and molecular features that make PCSK9 an attractive therapeutic target for cardiovascular diseases.
Various strategies for targeting PCSK9 and clinical trials involving PCSK9-inhibitors are also delineated.

First published: March 21, 2024  

In this infographic, we look at current treatment strategies and future innovations.

First published: November 8, 2023  

In this infographic, we look at the detection of calcified plaques, and how these could be used in primary prevention.

First published: September 1, 2023  

Our latest infographic discusses the role of combination therapy in lowering lipids in patients with ASCVD.

First published: July 20, 2023  

In this infographic, we look into managing the side effects of statin therapy with a particular focus on patient adherence.

First published: May 15, 2023  

This infographic summarizes the key take home messages of the World Heart Federation’s Cholesterol Roadmap.

First published: March 3, 2023  

Check out and download our latest infographic based on the 2022 Expert Consensus Decision Pathway by the American College of Cardiology – Role of Nonstatin Therapies in Lowering LDL-Cholesterol during ASCVD Risk Management.

First published: November 3, 2022  

Check out and download our latest infographic based on the consensus statement from the European Atherosclerotic Society (EAS) Congress, highlighting the role of Lp(a) in ASCVD and Aortic Stenosis.

First published: September 30, 2022  

Novel pharmacological interventions targeting lipids can lower the incidence of dyslipidaemia triggered cardiovascular events. Check out and download our latest infographic providing insights into evolution of lipid-lowering therapeutics and status of novel therapeutics highlighting their development, safety, and efficacy.

First published: August 8, 2022  

Statin therapy is a cornerstone for the prevention and treatment of CVD. However, statin associated muscle symptoms (SAMS) are serious side-effects of statin use and often lead to discontinuation of statin therapy. Check out and download our latest infographic highlighting the challenges, and recommendations for diagnosis and management of SAMS.

First published: May 24, 2022  

To mark the first Lipoprotein (a) awareness day on March 24, 2022, check out and download our latest infographic that highlights the role of Lp (a) in Familial Hypercholesterolaemia and ASCVD.

First published: March 24, 2022  

Check out and download our latest infographics highlighting the important findings of the REDUCE-IT Trials. The multicenter, placebo-controlled, double-blind trial REDUCE-IT assesses the therapeutic effects of icosapent ethyl, a stable eicosapentaenoic acid ethyl ester, in such patients.

First published: December 13, 2021